

Targeted Therapy of Cancer: New Prospects for Antibod

Ca-A Cancer Journal for Clinicians

56, 226-243

DOI: [10.3322/canjclin.56.4.226](https://doi.org/10.3322/canjclin.56.4.226)

Citation Report

#	ARTICLE	IF	CITATIONS
1	A Mechanistic Perspective of Monoclonal Antibodies in Cancer Therapy Beyond Target-Related Effects. <i>Oncologist</i> , 2007, 12, 1084-1095.	1.9	144
2	Blueprint for Imaging in Biomedical Research. <i>Radiology</i> , 2007, 244, 12-27.	3.6	27
3	The emerging role of molecular imaging and targeted therapeutics in peritoneal carcinomatosis. <i>Expert Opinion on Drug Delivery</i> , 2007, 4, 389-402.	2.4	17
4	The Era of Targeted Therapies. <i>Archives of Dermatology</i> , 2007, 143, 788-9.	1.7	3
6	Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view. <i>Nuclear Medicine and Biology</i> , 2007, 34, 757-778.	0.3	222
7	chFRP5-ZZ-PE38, a large IgG-toxin immunoconjugate outperforms the corresponding smaller FRP5(Fv)-ETA immunotoxin in eradicating ErbB2-expressing tumor xenografts. <i>Cancer Letters</i> , 2007, 257, 124-135.	3.2	22
8	Recent progress in the discovery of Akt inhibitors as anticancer agents. <i>Expert Opinion on Therapeutic Patents</i> , 2007, 17, 1077-1130.	2.4	37
9	Synthesis and Testing of a Binary Catalytic System for Imaging of Signal Amplification in Vivo. <i>Bioconjugate Chemistry</i> , 2007, 18, 1123-1130.	1.8	16
10	Improved Efficacy of ^{125}I -Targeted Albumin Conjugates by Conjugation of a Novel Auristatin Derivative. <i>Molecular Pharmaceutics</i> , 2007, 4, 686-694.	2.3	42
11	Affibody molecules: potential for in vivo imaging of molecular targets for cancer therapy. <i>Expert Opinion on Biological Therapy</i> , 2007, 7, 555-568.	1.4	117
13	Combined flow cytometry and confocal laser scanning microscopy for evaluation of BR96 antibody cancer cell targeting and internalization. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2007, 71A, 361-370.	1.1	4
14	Site-directed photoproteolysis of 8-oxoguanine DNA glycosylase 1 (OGG1) by specific porphyrin-protein probe conjugates: A strategy to improve the effectiveness of photodynamic therapy for cancer. <i>Journal of Photochemistry and Photobiology B: Biology</i> , 2007, 87, 9-17.	1.7	5
15	Monoclonal antibodies as therapeutic agents in oncology and antibody gene therapy. <i>Cell Research</i> , 2007, 17, 89-99.	5.7	51
16	Feasibility of the radioastatination of a monoclonal antibody with astatine-211 purified by wet extraction. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2008, 51, 379-383.	0.5	21
17	Identification of new accessible tumor antigens in human colon cancer by <i>ex vivo</i> protein biotinylation and comparative mass spectrometry analysis. <i>International Journal of Cancer</i> , 2008, 123, 2856-2864.	2.3	70
18	Multivalency: the hallmark of antibodies used for optimization of tumor targeting by design. <i>BioEssays</i> , 2008, 30, 904-918.	1.2	104
19	Trends in immunoconjugate and ligand-receptor based targeting development for cancer therapy. <i>Expert Opinion on Drug Delivery</i> , 2008, 5, 87-103.	2.4	23
20	Use of antibodies and immunoconjugates for the therapy of more accessible cancers. <i>Advanced Drug Delivery Reviews</i> , 2008, 60, 1407-1420.	6.6	54

#	ARTICLE	IF	CITATIONS
21	Anti-CD20 monoclonal antibody therapy in multiple myeloma. <i>British Journal of Haematology</i> , 2008, 141, 135-148.	1.2	98
22	Relationship between Animal Models and Clinical Research: Using Mucositis as a Practical Example. , 0, 81-108.		0
23	Antibody-cytokine fusion proteins: applications in cancer therapy. <i>Expert Opinion on Biological Therapy</i> , 2008, 8, 609-632.	1.4	45
24	Breast tumor targeting with ^{99m} Tc-HYNIC-PR81 complex as a new biologic radiopharmaceutical. <i>Nuclear Medicine and Biology</i> , 2008, 35, 763-768.	0.3	24
25	New frontiers in nanotechnology for cancer treatment. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2008, 26, 74-85.	0.8	274
26	Immunotherapy for Pediatric Cancer. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 33-43.	2.0	8
27	Rebuilding immunity in cancer patients. <i>Blood Cells, Molecules, and Diseases</i> , 2008, 40, 94-100.	0.6	20
29	Retrograde Delivery of Photosensitizer (TPPp-O- ¹²⁵ I-GluOH) ₃ Selectively Potentiates Its Photodynamic Activity. <i>Bioconjugate Chemistry</i> , 2008, 19, 532-538.	1.8	37
30	Antibody Conjugates of 7-Ethyl-10-hydroxycamptothecin (SN-38) for Targeted Cancer Chemotherapy. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 6916-6926.	2.9	115
31	Site-Specific, Thiol-Mediated Conjugation of Fluorescent Probes to Cysteine-Modified Diabodies Targeting CD20 or HER2. <i>Bioconjugate Chemistry</i> , 2008, 19, 2527-2534.	1.8	41
32	Update on Targeted Therapy-Focus on Monoclonal Antibodies. <i>Journal of Pharmacy Practice</i> , 2008, 21, 4-16.	0.5	7
33	Cancer gene therapy with targeted adenoviruses. <i>Expert Opinion on Drug Delivery</i> , 2008, 5, 1231-1240.	2.4	43
34	Multifunctional Antibodies by the Dock-and-Lock Method for Improved Cancer Imaging and Therapy by Pretargeting. <i>Journal of Nuclear Medicine</i> , 2008, 49, 158-163.	2.8	134
35	Development of Novel Tetravalent Anti-CD20 Antibodies with Potent Antitumor Activity. <i>Cancer Research</i> , 2008, 68, 2400-2408.	0.4	69
36	The role of photodynamic therapy (PDT) physics. <i>Medical Physics</i> , 2008, 35, 3127-3136.	1.6	179
37	An Examination of Chimpanzee Use in Human Cancer Research. <i>ATLA Alternatives To Laboratory Animals</i> , 2009, 37, 399-416.	0.7	16
38	EphA2 Immunoconjugate as Molecularly Targeted Chemotherapy for Ovarian Carcinoma. <i>Journal of the National Cancer Institute</i> , 2009, 101, 1193-1205.	3.0	78
39	Induction of Apoptosis by Cross-Linking Antibodies Bound to Human B-Lymphoma Cells: Expression of Annexin V Binding Sites on the Antibody Cap. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2009, 24, 185-193.	0.7	9

#	ARTICLE	IF	CITATIONS
41	Production of Antibodies against Multipass Membrane Proteins Expressed in Human Tumor Cells Using Dendritic Cell Immunization. <i>Journal of Biomedicine and Biotechnology</i> , 2009, 2009, 1-9.	3.0	13
42	Superior Antitumor Activity of SAR3419 to Rituximab in Xenograft Models for Non-Hodgkin's Lymphoma. <i>Clinical Cancer Research</i> , 2009, 15, 4038-4045.	3.2	53
43	Anti-tumor immune response in ovarian cancer: clinical implications, prognostic significance and potential for novel treatment strategies. <i>Oncology Reviews</i> , 2009, 3, 173-186.	0.8	0
44	Efficient production of human bivalent and trivalent anti-MUC1 Fab-scFv antibodies in <i>Pichia pastoris</i> . <i>BMC Biotechnology</i> , 2009, 9, 70.	1.7	34
45	Natural killer cell-based immunotherapy in cancer: current insights and future prospects. <i>Journal of Internal Medicine</i> , 2009, 266, 154-181.	2.7	180
46	A GUTLESS ADENOVIRAL VECTOR EXPRESSING FULL-LENGTH ANTI-Her2 ANTIBODY. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2009, 36, e26-31.	0.9	3
48	EGFR-Nrf2 pathway plays a role in cancer cell's chemoresistance. <i>Bioscience Hypotheses</i> , 2009, 2, 261-263.	0.2	4
50	Novel strategies for improved cancer vaccines. <i>Expert Review of Vaccines</i> , 2009, 8, 567-576.	2.0	19
51	Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody. <i>Blood</i> , 2009, 113, 1062-1070.	0.6	115
52	Improving the efficacy of combined modality anticancer therapy using HPMA copolymer-based nanomedicine formulations†. <i>Advanced Drug Delivery Reviews</i> , 2010, 62, 203-230.	6.6	110
53	Synthesis and Preliminary Biological Evaluation of High-Drug-Load Paclitaxel-Antibody Conjugates for Tumor-Targeted Chemotherapy. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 586-594.	2.9	60
54	Polymeric nanomedicines for image-guided drug delivery and tumor-targeted combination therapy. <i>Nano Today</i> , 2010, 5, 197-212.	6.2	126
55	Preparation of near-infrared quantum dots-herceptin conjugates for cancer imaging. <i>Macromolecular Research</i> , 2010, 18, 641-647.	1.0	3
56	Distribution, cellular localization, and therapeutic potential of the tumor-associated antigen Ku70/80 in glioblastoma multiforme. <i>Journal of Neuro-Oncology</i> , 2010, 97, 207-215.	1.4	9
57	Injectable intratumoral depot of thermally responsive polypeptide-radiionuclide conjugates delays tumor progression in a mouse model. <i>Journal of Controlled Release</i> , 2010, 144, 2-9.	4.8	102
58	Introduction to the supplement, "Cancer Therapy with Antibodies and Immunoconjugates". <i>Cancer</i> , 2010, 116, 1011-1012.	2.0	0
59	The influence of proteasome inhibitor MG132, external radiation, and unlabeled antibody on the tumor uptake and biodistribution of ¹⁸⁸ Re-labeled anti-CE6 C1P5 antibody in cervical cancer in mice. <i>Cancer</i> , 2010, 116, 1067-1074.	2.0	19
60	Targeted Therapy Database (TTD): A Model to Match Patient's Molecular Profile with Current Knowledge on Cancer Biology. <i>PLoS ONE</i> , 2010, 5, e11965.	1.1	18

#	ARTICLE	IF	CITATIONS
61	High Rates of Durable Responses With Anti-CD22 Fractionated Radioimmunotherapy: Results of a Multicenter, Phase I/II Study in Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2010, 28, 3709-3716.	0.8	106
62	Construction and Characterization of a Bispecific Anti-CD20 Antibody with Potent Antitumor Activity against B-Cell Lymphoma. <i>Cancer Research</i> , 2010, 70, 6293-6302.	0.4	7
63	Immune Response in Ovarian Cancer: How Is the Immune System Involved in Prognosis and Therapy: Potential for Treatment Utilization. <i>Clinical and Developmental Immunology</i> , 2010, 2010, 1-15.	3.3	44
64	Veltuzumab (humanized anti-CD20 monoclonal antibody): characterization, current clinical results, and future prospects. <i>Leukemia and Lymphoma</i> , 2010, 51, 747-755.	0.6	52
65	HPMA-based polymer therapeutics improve the efficacy of surgery, of radiotherapy and of chemotherapy combinations. <i>Nanomedicine</i> , 2010, 5, 1501-1523.	1.7	18
66	Radioactive Antibodies: A Historical Review of Selective Targeting and Treatment of Cancer. <i>Hospital Practice (1995)</i> , 2010, 38, 82-93.	0.5	9
67	Bevacizumab in combination with sequential high-dose chemotherapy in solid cancer, a feasibility study. <i>Bone Marrow Transplantation</i> , 2010, 45, 1704-1709.	1.3	6
68	Radioimmunotherapy with an antibody to the HPV16 E6 oncoprotein is effective in an experimental cervical tumor expressing low levels of E6. <i>Cancer Biology and Therapy</i> , 2010, 10, 1041-1047.	1.5	11
69	Novel anti-CD20 antibody TGLA with enhanced antibody-dependent cell-mediated cytotoxicity mediates potent anti-lymphoma activity. <i>Cancer Letters</i> , 2010, 294, 66-73.	3.2	6
70	A tandem scFv-based fusion protein and its enediyne-energized analogue show intensified therapeutic efficacy against lung carcinoma xenograft in athymic mice. <i>Cancer Letters</i> , 2010, 295, 124-133.	3.2	31
71	Receptor-targeted nanocarriers for therapeutic delivery to cancer. <i>Molecular Membrane Biology</i> , 2010, 27, 286-298.	2.0	285
72	In Situ Mapping of Membranolytic Peptide-Membrane Interactions by Coupled Attenuated Total Reflection Fourier-Transform Infrared Spectroscopy-Atomic Force Microscopy (ATR-FTIR-AFM). <i>Biophysical Journal</i> , 2011, 100, 350a-351a.	0.2	0
73	Monoclonal Antibodies in Paediatric Acute Lymphoblastic Leukemia. , 2011, , 221-271.		3
74	Engineering Antibodies for Cancer Therapy. <i>Annual Review of Chemical and Biomolecular Engineering</i> , 2011, 2, 53-75.	3.3	26
75	Breast Cancer: Radioimmunoscinigraphy and Radioimmunotherapy. , 0, , .		1
76	The intraportal injection model for liver metastasis. <i>Nuclear Medicine Communications</i> , 2011, 32, 147-154.	0.5	17
77	Antibody Conjugate Therapeutics: Challenges and Potential. <i>Clinical Cancer Research</i> , 2011, 17, 6389-6397.	3.2	365
78	Radioimmunotherapy of experimental head and neck squamous cell carcinoma (HNSCC) with E6-specific antibody using a novel HPV-16 positive HNSCC cell line. <i>Head & Neck Oncology</i> , 2011, 3, 9.	2.3	26

#	ARTICLE	IF	CITATIONS
79	The Immune Response to Tumors as a Tool toward Immunotherapy. <i>Clinical and Developmental Immunology</i> , 2011, 2011, 1-12.	3.3	40
80	Molecularly targeted therapy in neuro-oncology. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2012, 104, 255-278.	1.0	9
81	Radioimmunotherapy in Metastatic Colorectal Cancer. <i>Medical Radiology</i> , 2012, , 639-661.	0.0	0
82	Antitumor efficacy of the scFv-based fusion protein and its enediyne-energized analogue directed against epidermal growth factor receptor. <i>Anti-Cancer Drugs</i> , 2012, 23, 406-416.	0.7	9
83	The Design of Hybrid Nanoparticles for Image-Guided Radiotherapy. <i>ACS Symposium Series</i> , 2012, , 95-143.	0.5	2
84	Therapeutic application of monoclonal antibodies in cancer: advances and challenges. <i>British Medical Bulletin</i> , 2012, 104, 41-59.	2.7	65
85	A novel ligand delivery system to non-invasively visualize and therapeutically exploit the IL13R α 2 tumor-restricted biomarker. <i>Neuro-Oncology</i> , 2012, 14, 1239-1253.	0.6	12
86	Dual mechanism of action of ingenol mebutate gel for topical treatment of actinic keratoses: Rapid lesion necrosis followed by lesion-specific immune response. <i>Journal of the American Academy of Dermatology</i> , 2012, 66, 486-493.	0.6	161
87	Antibody-“drug conjugates” a perfect synergy. <i>Expert Opinion on Biological Therapy</i> , 2012, 12, 1191-1206.	1.4	98
88	Antibodies for Nuclear Medicine Therapy. <i>Medical Radiology</i> , 2012, , 125-138.	0.0	0
89	Targeted Alpha Particle Therapy of Peritoneal Carcinomas. <i>Medical Radiology</i> , 2012, , 557-567.	0.0	0
90	Drug Delivery Systems to Fight Cancer. , 2012, , 493-516.		4
92	Pre-Clinical Evaluation of a ²¹³ Bi-Labeled 2556 Antibody to HIV-1 gp41 Glycoprotein in HIV-1 Mouse Models as a Reagent for HIV Eradication. <i>PLoS ONE</i> , 2012, 7, e31866.	1.1	32
93	Human antibodies targeting CD30+ lymphomas. <i>Human Antibodies</i> , 2012, 21, 13-28.	0.6	10
94	Prevention of Oncological Diseases: Primary and Secondary Prevention. <i>International Journal of Biological Markers</i> , 2012, 27, 337-343.	0.7	4
95	Pretargeting: taking an alternate route for localizing radionuclides. <i>Tumor Biology</i> , 2012, 33, 591-600.	0.8	28
96	Drug targeting to tumors: Principles, pitfalls and (pre-) clinical progress. <i>Journal of Controlled Release</i> , 2012, 161, 175-187.	4.8	1,131
97	Cancer therapy and vaccination. <i>Journal of Immunological Methods</i> , 2012, 382, 1-23.	0.6	58

#	ARTICLE	IF	CITATIONS
98	Nanocarriers for delivery of platinum anticancer drugs. <i>Advanced Drug Delivery Reviews</i> , 2013, 65, 1667-1685.	6.6	345
99	The therapeutic efficacy of I131-PSCA-mAb in orthotopic mouse models of prostate cancer. <i>European Journal of Medical Research</i> , 2013, 18, 56.	0.9	11
100	The Chemistry of Therapeutic Radiopharmaceuticals. , 2013, , 339-368.		5
101	Biological rationale for the design of polymeric anti-cancer nanomedicines. <i>Journal of Drug Targeting</i> , 2013, 21, 1-26.	2.1	63
102	Targeting EGFR ⁺ positive cancer cells with cetuximab ⁺ PE38: Results of in vitro and in vivo studies. <i>Head and Neck</i> , 2013, 35, 1171-1177.	0.9	9
103	Nanodosimetry of Auger electrons: A case study from the decay of ^{125}I and $^{18}\text{-eV}$ electron stopping cross sections of cytosine. <i>Physical Review E</i> , 2013, 87, .	0.8	11
104	Radioimmunotherapy for peritoneal cancers. <i>Immunotherapy</i> , 2013, 5, 395-405.	1.0	8
105	Combined treatment of the experimental human papilloma virus-16-positive cervical and head and neck cancers with cisplatin and radioimmunotherapy targeting viral E6 oncoprotein. <i>British Journal of Cancer</i> , 2013, 108, 859-865.	2.9	14
106	Biological Therapies for Cancer. , 2013, , 303-342.		2
107	Doxorubicin-conjugated bacteriophages carrying anti-MHC class I chain-related A for targeted cancer therapy in vitro. <i>OncoTargets and Therapy</i> , 2014, 7, 2183.	1.0	5
108	Antibody ⁺ Drug Conjugates Delivering DNA Cytotoxics. , 2014, , 479-490.		1
109	Antibodies directed against receptor tyrosine kinases. <i>MAbs</i> , 2014, 6, 838-851.	2.6	67
110	Antibody drug conjugates. <i>Current Opinion in Oncology</i> , 2014, 26, 476-483.	1.1	16
111	Monovinyl Sulfone β -Cyclodextrin. A Flexible Drug Carrier System. <i>ChemMedChem</i> , 2014, 9, 383-389.	1.6	19
112	Vectors for the delivery of radiopharmaceuticals in cancer therapeutics. <i>Therapeutic Delivery</i> , 2014, 5, 893-912.	1.2	2
113	¹⁷⁷ Lu-Labeled Antibodies for EGFR-Targeted SPECT/CT Imaging and Radioimmunotherapy in a Preclinical Head and Neck Carcinoma Model. <i>Molecular Pharmaceutics</i> , 2014, 11, 800-807.	2.3	38
114	The development of immunoconjugates for targeted cancer therapy. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 637-648.	12.5	83
115	Antibody ⁺ drug conjugates as novel anti-cancer chemotherapeutics. <i>Bioscience Reports</i> , 2015, 35, .	1.1	327

#	ARTICLE	IF	CITATIONS
116	Recent advances in the field of anti-cancer immunotherapy. <i>BBA Clinical</i> , 2015, 3, 280-288.	4.1	72
117	Targeted therapy of solid tumors by monoclonal antibody specific to epidermal growth factor receptor. <i>Human Antibodies</i> , 2015, 23, 13-20.	0.6	7
118	¹⁸⁸ Re-HYNIC-trastuzumab enhances the effect of apoptosis induced by trastuzumab in HER2-overexpressing breast cancer cells. <i>Annals of Nuclear Medicine</i> , 2015, 29, 52-62.	1.2	13
119	Novel Use of Terpenoids for Treatment of Dermatologic Diseases: A Systematic Review of Clinical Trials. <i>Journal of Alternative and Complementary Medicine</i> , 2015, 21, 261-268.	2.1	3
120	Optimization of anti-CD20 humanized antibody hu8E4 by site-directed mutation based on epitope analysis. <i>Biochemical and Biophysical Research Communications</i> , 2015, 459, 617-622.	1.0	3
121	Monoclonal Antibodies as Therapeutic Agents. , 2016, , 157-196.		1
122	Reprogramming of Normal Fibroblasts into Cancer-Associated Fibroblasts by miRNAs-Mediated CCL2/VEGFA Signaling. <i>PLoS Genetics</i> , 2016, 12, e1006244.	1.5	70
123	A “Double-Edged” Scaffold: Antitumor Power within the Antibacterial Quinolone. <i>Current Medicinal Chemistry</i> , 2016, 23, 520-577.	1.2	33
124	Design of smart GE11-PLGA/PEG-PLGA blend nanoparticulate platforms for parenteral administration of hydrophilic macromolecular drugs: synthesis, preparation and in vitro/ex vivo characterization. <i>International Journal of Pharmaceutics</i> , 2016, 511, 1112-1123.	2.6	31
125	A leucine zipper pair-based lipid vesicle for image-guided therapy in breast cancer. <i>Chemical Communications</i> , 2016, 52, 2687-2690.	2.2	1
126	Nanostructured materials functionalized with metal complexes: In search of alternatives for administering anticancer metallodrugs. <i>Coordination Chemistry Reviews</i> , 2016, 312, 67-98.	9.5	183
127	Colorimetric Biosensor for Detection of Cancer Biomarker by Au Nanoparticle-Decorated Bi ₂ Se ₃ Nanosheets. <i>ACS Applied Materials & Interfaces</i> , 2017, 9, 6931-6940.	4.0	131
128	Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)“Positive Metastatic Breast Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 37.	3.8	129
131	Development versus Evolution in Cancer Biology. <i>Trends in Cancer</i> , 2018, 4, 342-348.	3.8	15
132	High-throughput oxidation screen of antibody“drug conjugates by analytical protein A chromatography following IdeS digest. <i>Journal of Pharmacy and Pharmacology</i> , 2018, 70, 625-635.	1.2	7
133	Chitosan (CMD)-mediated co-delivery of SN38 and Snail-specific siRNA as a useful anticancer approach against prostate cancer. <i>Pharmacological Reports</i> , 2018, 70, 418-425.	1.5	31
134	The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target. <i>Oncotarget</i> , 2018, 9, 28989-29006.	0.8	169
135	Impact of Payload Hydrophobicity on the Stability of Antibody“Drug Conjugates. <i>Molecular Pharmaceutics</i> , 2018, 15, 2656-2664.	2.3	61

#	ARTICLE	IF	CITATIONS
136	A pharmacokinetics phase 1 bioequivalence study of the trastuzumab biosimilar MYL401O vs. EU-trastuzumab and US-trastuzumab. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 2336-2343.	1.1	25
137	Antibody-Drug Conjugates for Cancer Therapy: Chemistry to Clinical Implications. <i>Pharmaceuticals</i> , 2018, 11, 32.	1.7	161
138	GE11 Peptide as an Active Targeting Agent in Antitumor Therapy: A Minireview. <i>Pharmaceuticals</i> , 2018, 10, 2.	2.0	69
139	Antibody-drug conjugates (ADCs): Potent biopharmaceuticals to target solid and hematological cancers- an overview. <i>Journal of Drug Delivery Science and Technology</i> , 2018, 48, 106-117.	1.4	16
140	Antibody fusion proteins with human ribonucleases 1 to 8. <i>Human Antibodies</i> , 2018, 26, 177-192.	0.6	3
141	Bispecific Antibodies: Formats and Areas of Application. <i>Molecular Biology</i> , 2018, 52, 323-334.	0.4	3
142	Efficacy and safety of MYL501D versus insulin glargine in patients with type 2 diabetes after 24 weeks: Results of the phase III INSTRIDE 2 study. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 129-135.	2.2	20
143	Radiobromine and radioiodine for medical applications. <i>Radiochimica Acta</i> , 2019, 107, 1033-1063.	0.5	16
144	Innovative approaches for cancer treatment: current perspectives and new challenges. <i>Ecancermedalscience</i> , 2019, 13, 961.	0.6	450
145	Residual Seal Force Testing: A Suitable Method for Seal Quality Determination of (High Potent) Parenterals. <i>PDA Journal of Pharmaceutical Science and Technology</i> , 2019, 73, 111-120.	0.3	2
146	Antibody-drug therapeutic conjugates: Potential of antibody-siRNAs in cancer therapy. <i>Journal of Cellular Physiology</i> , 2019, 234, 16724-16738.	2.0	15
147	Mediators of Inflammation in Topical Therapy of Skin Cancers. <i>Mediators of Inflammation</i> , 2019, 2019, 1-15.	1.4	33
148	Vibrational spectroscopy as a tool for examination to the secondary structure of metal-labeled trastuzumab immunoconjugates. <i>Journal of Radioanalytical and Nuclear Chemistry</i> , 2019, 320, 209-218.	0.7	1
149	Bivalent Peptide- and Chelator-Containing Bioconjugates as Toolbox Components for Personalized Nanomedicine. <i>Biomacromolecules</i> , 2020, 21, 199-213.	2.6	8
150	FGF2-Derived PeptibodyF2-MMAE Conjugate for Targeted Delivery of Cytotoxic Drugs into Cancer Cells Overexpressing FGFR1. <i>Cancers</i> , 2020, 12, 2992.	1.7	5
151	Development of the Bispecific Antibody in Fab-scFv Format Based on an Antibody to Human Interferon Beta-1 and Antibody to HER2 Receptor. <i>Russian Journal of Bioorganic Chemistry</i> , 2020, 46, 572-581.	0.3	0
152	Molecular targeted therapy: novel therapeutic approach for head and neck cancer. <i>Therapeutic Delivery</i> , 2020, 11, 637-651.	1.2	4
153	Targeting Glycosylation: A New Road for Cancer Drug Discovery. <i>Trends in Cancer</i> , 2020, 6, 757-766.	3.8	155

#	ARTICLE	IF	CITATIONS
154	Effect of Linker-Drug Properties and Conjugation Site on the Physical Stability of ADCs. <i>Journal of Pharmaceutical Sciences</i> , 2020, 109, 1662-1672.	1.6	11
155	In vivo anti-MUC1+ tumor activity and sequences of high-affinity anti-MUC1-SEA antibodies. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1337-1352.	2.0	15
156	Sacituzumab govitecan, a novel, third-generation, antibody-drug conjugate (ADC) for cancer therapy. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 871-885.	1.4	57
157	Potent in vitro antitumor activity of B-subunit of Shiga toxin conjugated to the diphtheria toxin against breast cancer. <i>European Journal of Pharmacology</i> , 2021, 899, 174057.	1.7	11
158	The Cellular and Chemical Biology of Endocytic Trafficking and Intracellular Deliveryâ€”The GLâ€”Lect Hypothesis. <i>Molecules</i> , 2021, 26, 3299.	1.7	8
159	Final overall survival analysis of the phase 3 HERITAGE study demonstrates equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 188, 369-377.	1.1	6
160	Correlation between week 24 trastuzumab-dkst response and week 48 progression-free survival: the HERITAGE trial. <i>Breast</i> , 2021, 58, 18-26.	0.9	3
161	Physicochemical and functional characterization of trastuzumab-dkst, a trastuzumab biosimilar. <i>Future Medicinal Chemistry</i> , 2021, 13, 1531-1557.	1.1	0
162	A Bayesian adaptive design for biosimilar trials with timeâ€”toâ€”event endpoint. <i>Pharmaceutical Statistics</i> , 2021, 20, 597-609.	0.7	1
163	Cancer Immunotherapy: Perspectives and Prospects. , 2008, 622, 235-253.		3
164	Immuno-PET imaging based radioimmunotherapy in head and neck squamous cell carcinoma model. <i>Oncotarget</i> , 2017, 8, 92090-92105.	0.8	20
165	CEACAM1 is a Privileged Cell Surface Antigen to Design Novel ScFv Mediated-Immunotherapies of Melanoma, Lung Cancer and Other Types of Tumors. <i>The Open Pharmacology Journal</i> , 2012, 6, 1-11.	0.4	3
166	Designing and Analyzing the Structure of DT-STXB Fusion Protein as an Anti-tumor Agent: An in Silico Approach. , 2019, 14, 305-312.		11
167	Conditional inactivation of HIF-1 using intrabodies. <i>Cellular Oncology</i> , 2008, 30, 397-409.	1.9	10
168	Modern Technologies for Creating Synthetic Antibodies for Clinical Application. <i>Acta Naturae</i> , 2009, 1, 32-50.	1.7	66
169	Mutation detection and molecular targeted tumor therapies. <i>STEMedicine</i> , 2020, 1, e11.	0.5	31
170	Radiolabelled Monoclonal Antibodies in the Treatment of Metastatic Cancer. <i>Current Oncology</i> , 2007, 14, 39-42.	0.9	6
172	Monoclonal Antibodies as Therapeutic Agents. , 2008, , 107-126.		0

#	ARTICLE	IF	CITATIONS
173	Combination therapy with cell-binding domain, angiogenesis inhibitor and Ca ²⁺ channel blocker in mice metastatic model. <i>Annals of Cancer Research and Therapy</i> , 2008, 16, 31-35.	0.1	0
174	Pharmaceutical Perspectives of Cancer Therapeutics: Current Therapeutic Uses of Monoclonal Antibodies. , 2009, , 321-363.		0
175	Immunoconjugate Anticancer Therapeutics. , 2010, , 371-392.		1
176	Antibody Radiolabeling. , 2010, , 323-344.		0
177	Miscleavage-Based Diseases. , 2009, , 403-408.		1
179	Targeted Therapy in Hematologic Malignancies. , 2011, , 293-323.		0
181	Targeted Toxins in Cancer Immunotherapy. , 2013, , 377-396.		0
182	Cardiovascular complications of selected antibodies used in oncological immunotherapy. <i>OnCORreview</i> , 2017, 7, 78-82.	0.1	0
183	PREPARATION AND INTEGRITY EXAMINATION OF FREEZE DRIED KIT OF TRASTUZUMAB-IMMUNOCONJUGATES AND COLD LABELED IMMUNOCONJUGATES BY APPLYING SDS-PAGE ELECTROPHORESIS. <i>Acta Medica Medianae</i> , 2019, , 15-23.	0.0	0
184	The molecular genetics of breast cancer and targeted therapy. <i>Biologics: Targets and Therapy</i> , 2007, 1, 241-58.	3.0	18
185	Modern Technologies for Creating Synthetic Antibodies for Clinical application. <i>Acta Naturae</i> , 2009, 1, 32-50.	1.7	41
186	Nanodosimetry of Auger electrons: A case study from the decay of I and O-18-eV electron stopping cross sections of cytosine. <i>Physical Review E</i> , 2013, 87, 0327011-327014.	0.8	2
187	Intrabody Targeting HIF-1 α Mediates Transcriptional Downregulation of Target Genes Related to Solid Tumors. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12335.	1.8	2
188	Peptibody Based on FGFR1-Binding Peptides From the FGF4 Sequence as a Cancer-Targeting Agent. <i>Frontiers in Pharmacology</i> , 2021, 12, 748936.	1.6	3
190	Recent Development of Monoclonal Antibodies Targeting Tyrosine Kinase in ROS-Mediated Cancer. , 2021, , 1-16.		0
191	Recent Development of Monoclonal Antibodies Targeting Tyrosine Kinase in ROS-Mediated Cancer. , 2022, , 383-398.		0
192	Valid-NEO: A Multi-Omics Platform for Neoantigen Detection and Quantification from Limited Clinical Samples. <i>Cancers</i> , 2022, 14, 1243.	1.7	3
196	Optimization of the assembly efficiency for lidamycin chromophore bound to its apoprotein: a case study using orthogonal array. <i>Biomedical and Environmental Sciences</i> , 2011, 24, 602-7.	0.2	5

#	ARTICLE	IF	CITATIONS
198	Clinical Dose Preparation of [¹⁷⁷ Lu]Lu-DOTA-Pertuzumab Using Medium Specific Activity [¹⁷⁷ Lu]LuCl ₃ for Radioimmunotherapy of Breast and Epithelial Ovarian Cancers, with HER2 Receptor Overexpression. Cancer Biotherapy and Radiopharmaceuticals, 2022, 37, 384-402.	0.7	2
199	The Molecular Biology of Apoptosis. Turkish Journal of Veterinary Research, 0, , .	0.5	0
200	Antibody-drug conjugates for targeted delivery. , 2022, , 377-419.		0
201	CuAAC ensembled 1,2,3-triazole linked nanogels for targeted drug delivery: a review. RSC Advances, 2023, 13, 2912-2936.	1.7	9
202	Smart Biomimetic Nanozymes for Precise Molecular Imaging: Application and Challenges. Pharmaceuticals, 2023, 16, 249.	1.7	3
203	Precision Medicine: Translation of Individualistic Treatment in Oncology. , 2023, , 77-149.		0
204	Cancer treatment therapies: traditional to modern approaches to combat cancers. Molecular Biology Reports, 2023, 50, 9663-9676.	1.0	2